Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease.
Lees A, Fahn S, Eggert KM, Jankovic J, Lang A, Micheli F, Mouradian MM, Oertel WH, Olanow CW, Poewe W, Rascol O, Tolosa E, Squillacote D, Kumar D.
Lees A, et al. Among authors: squillacote d.
Mov Disord. 2012 Feb;27(2):284-8. doi: 10.1002/mds.23983. Epub 2011 Dec 9.
Mov Disord. 2012.
PMID: 22161845
Clinical Trial.